Aim:　This　study　aimed　to　investigate　post-marketing　adverse　events　(AEs)　of　interleukin-6　(IL-6)　inhibitors,　and　to　explore　risk　factors　for　death.　Method:　Disproportionality　analyses　were　conducted　on　adverse　event　cases　of　IL-6　inhibitors　reported　to　the　US　Food　and　Drug　Administration　Adverse　Event　Reporting　System　(FAERS)　from　the　time　of　drug　launch　until　the　fourth　quarter　of　2023.　Univariate　and　multivariate　logistic　regression　analyses　were　carried　out　utilizing　patient-related　clinical　information,　and　prediction　models　for　IL-6　inhibitor-related　mortality　risk　were　developed　by　incorporating　patient　age　and　weight　factors.　Results:　A　total　of　63,445　reports　were　retrieved,　with　the　majority　of　known　age　groups　falling　between　18　and　64　years.　Most　reports　were　submitted　by　consumers　and　physicians,　predominantly　from　the　United　States.　Tocilizumab　was　associated　with　AEs　such　as　drug　intolerance　and　infection,　while　sarilumab　showed　symptoms　of　pain　and　condition　aggravated.　Siltuximab　was　linked　to　disease　progression　and　thrombocytopenia.　The　median　time　to　AEs　with　IL-6　inhibitors　was　74　days　(interquartile　range　[IQR]　10-311),　mostly　occurring　within　1　month.　Factors　such　as　age,　propionic　acid　derivative,　infections　and　infestations,　nervous　system　disorders,　and　immune　system　disorders　were　independent　risk　factors　for　deaths　related　to　IL-6　inhibitor　use　(p　＜　0.05).　The　mortality　risk　prediction　model　demonstrated　good　discriminatory　power　and　clinical　applicability　in　both　the　training　set　(AUC　0.6968)　and　the　validation　set　(AUC　0.7502).　Conclusion:　Our　postmarketing　pharmacovigilance　analysis　revealed　the　types　and　incidence　of　AEs　related　to　IL-6　inhibitors.　Column　line　diagrams　may　be　useful　for　clinical　assessment　of　the　occurrence　of　death　and　have　high　clinical　utility.　Copyright　©　2025　Meilin　Fang　et　al.　Journal　of　Clinical　Pharmacy　and　Therapeutics　published　by　John　Wiley　&　Sons　Ltd.